Organization
Department of Abdominal and Pelvic Medical Oncology, The First People's Hospital of Tianmen City, Affiliated Hospital of Hubei Technology College, Tianmen, China
1 abstract
Abstract
Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.Org: Department of Abdominal and Pelvic Medical Oncology, The First People's Hospital of Tianmen City, Affiliated Hospital of Hubei Technology College, Tianmen, China,